Follow The Leader: The cost of listening to only 1 guideline
Case Presentation
Setting: American College of Cardiology (ACC) 62nd Annual Scientific Session, San Francisco, CA | March 9-11, 2013
A packed crowd, spilling out into the foyer of the lecture hall, awaited the much anticipated release of the new 2013 ACC/AHA Blood Cholesterol Guidelines. They weren't quite ready and they were not released at that time, so a Q&A session with the Guideline writing committee members was held instead, offering a hint of what we might expect from these guidelines.
Based on what they had already heard, an audience participant asked one of the Guideline writers what they would do in the following situation:
The Scenario: A patient who had had an ASCVD event who was placed on a maximum high intensity statin, like Atorvastatin 80 mg daily, but achieved an on-treatment LDL-C of just over 100 mg/dL (previous guidelines called for LDL < 70 mg/dL). What next?
Guideline writer's reply: "I think you're done."
This was a stark departure from prior and existing guidelines and in this particular scenario, offered a treatment strategy that was inferior to the current standard of care, leaving countless high risk patients at risk for undertreatment and exposing them unnecessarily to excess residual risk.
It seemed to promote the outdated "fire and forget" strategy (enjoyed by the lazy practitioner), where all you needed to do was place your high risk patients on a "high intensity statin" and call it a day. "Poof", done. Never check a lipid panel again. Obviously, that's not exactly what was said, nor intended by the Guideline Committee, but that's how it was received by many.
Flying Under the Radar
"But my doctor is following the guidelines - is it possible that I am being undertreated?" Yes, it is. Providers are human and they often "follow the leader." When it comes to cardiovascular guidelines, the leader is often the American College of Cardiology and the American Heart Association (ACC/AHA).
However guidelines are just that - guidelines. They don't always apply to everyone (for instance, certain ethnic groups). They don't always apply to every situation. There are many of them out there and they're not always created equal. And yes, as well respected as these organizations are, sometimes they get it wrong. That was the case with the 2013 ACC/AHA Blood Cholesterol Guidelines. They were well intentioned and they had their reasons, but it was a swing and a miss and set the lipid community back several years.
CardioAdvocate Checklist
For Patients and Providers
- Highest Risk — Secondary prevention: >20% ten year risk of ASCVD event, CAC >300, Familial Hypercholesterolemia, Elevated Lp(a) >325 nmol/L, High lifetime risk
- Use the PREVENT-ASCVD calculator (2026 update) for 10-year and 30-year risk estimation. This replaced the Pooled Cohort Equations in 2026. New risk tiers: Low (<3%), Borderline (3-<5%), Intermediate (5-<10%), High (≥10%)
- Also use multiple additional risk calculators for cross-validation: Reynolds (includes family history and hs CRP), Framingham, and European HeartScore
Recommended Resources
- PREVENT-ASCVD Calculator (AHA) — 10-year and 30-year risk estimation (2026)
- Mayo Clinic Statin Choice Decision Aid — Contains multiple risk calculators
- LearnYourLipids — Find a clinician specializing in lipid management
Expert Thought Leaders
Deep Dive
The 2013 ACC/AHA Blood Cholesterol Guidelines: An Interesting Story
The 2013 ACC/AHA Blood Cholesterol Guidelines were created under the strictest interpretation of "Evidence Based Medicine," allowing only for data obtained from Randomized Controlled Trials (RCT) and/or meta-analysis of Randomized Controlled Trials in crafting recommendations. This painted them into a corner and effectively created a situation where they undermined existing guidelines and were forced to abandon any sort of lipid goal or target. Instead, they vehemently declared that clinical trials to date had only shown that a particular dose of statin had achieved the positive outcomes, rather than a particular LDL-C goal attained, for instance.
Historical Context: The Path to 2013
Since 1985 the National Cholesterol Education Program has been managed by the NHLBI, a division of the NIH and produced guidelines on cholesterol. The last guideline published was the Adult Treatment Panel III (NCEP ATPIII) in 2001 and updated in 2004 (ATP III Report on High Blood Cholesterol) to include an optional goal of LDL-C < 70 mg/dL for very high risk patients. Its 284 pages is a tour de force in how to write a guideline. It was chaired by Scott Grundy M.D., Ph.D., a legend in the field of atherosclerosis. The guideline reviewed and appropriately weighted the totality of available scientific evidence, providing useful and balanced recommendations. Within its text is an abundance of educational material to include the criteria for metabolic syndrome. It remains a great resource for anyone interested in understanding atherosclerosis.
The next iteration of guidelines were nearly complete, when in 2013 the NHLBI decided to no longer participate in the publication of various cardiometabolic guidelines to include cholesterol, high blood pressure, obesity and nutrition, turning these duties over to various stakeholders such as the ACC/AHA for the cholesterol guidelines. The guidelines writers remained intact. In trying to adhere to the Institute of Medicine's "guidelines for writing evidence-based guidelines," which prioritized RCTs above all other sources of evidence, it decided to completely restrict the 2013 Blood Cholesterol Guidelines from anything but RCT data, rather than simply prioritizing it.
Populations and Disparities: What About Other Ethnic Groups?
Many ethnic groups have published lipid guidelines or consensus statements more applicable to their risk, such as:
- Lipid Association of India — Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies
- Asian Pacific Society of Cardiology — Consensus Recommendations on Dyslipidaemia
- Veterans Affairs/DOD Clinical Practice Guidelines — The Management of Dyslipidemia for Cardiovascular Risk Reduction (2020)
The Challenge of Standardization: Lipid Goals by Risk Categories
Unfortunately, as is often the case in medicine when multiple stakeholders are involved, there is no standardization of nomenclature when it comes to defining and categorizing risk. We have attempted to break down some of the more popular guidelines and statements with their respective risk categories, definitions and related lipid goals and recommendations.
AACE/ACE Risk Categories
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary
Extreme Risk
Risk Factors:
- Progressive ASCVD including unstable angina
- Established clinical ASCVD + diabetes or CKD ≥3 or HeFH
- History of premature ASCVD (<55y Male, <65y Female)
Treatment Goals:
- LDL-C <55 mg/dL "and" ≥50% reduction from baseline
- Non-HDL-C <70 mg/dL
- ApoB <70 mg/dL
- TG <150 mg/dL
Very High Risk
Risk Factors:
- Established clinical ASCVD or recent hospitalization for ACS, carotid or peripheral vascular disease, or 10 y risk >20%
- Diabetes w/ ≥1 risk factor
- CKD ≥3 w/ albuminuria
- HeFH
Treatment Goals:
- LDL-C <70 mg/dL "and" ≥50% reduction from baseline
- Non-HDL-C <100 mg/dL
- ApoB <80 mg/dL
- TG <150 mg/dL
High Risk
Risk Factors:
- ≥2 risk factors & 10 y risk >10-20%
- Diabetes or CKD ≥3 & no other risk factors
- ≥3 & no other risk factors
Treatment Goals:
- LDL-C <70 mg/dL "and" ≥50% reduction from baseline
- Non-HDL-C <100 mg/dL
- ApoB <80 mg/dL
- TG <150 mg/dL
Moderate Risk
Risk Factors:
- <2 risk factors & 10 y risk <10%
Treatment Goals:
- LDL-C <100 mg/dL
- Non-HDL-C <130 mg/dL
- ApoB <90 mg/dL
- TG <150 mg/dL
Low Risk
Risk Factors:
- No risk factors
Treatment Goals:
- LDL-C <130 mg/dL
- Non-HDL-C <160 mg/dL
- ApoB - not recommended
- TG <150 mg/dL
ESC/EAS Risk Categories
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Very High Risk
Risk Factors:
- Recurrent ASCVD events (more than 1)
- Extensive atherosclerotic cardiovascular disease
- Higher global cardiovascular risk scores
Lipid Goals (Primary or Secondary Prevention):
- LDL-C <55 mg/dL "and" ≥50% reduction from "baseline"
- LDL-C <40 mg/dL — Patients with ASCVD with another vascular event within 2 years (not necessarily the same type of event)
- Non-HDL-C <85 mg/dL
- Apolipoprotein B (ApoB) <65 mg/dL
High Risk
Risk Factors:
- Markedly elevated single risk factor (LDL-C ≥190 mg/dL - severe hypercholesterolemia including FH; BP ≥180/110 mmHg)
- Familial Hypercholesterolemia (FH) without any additional risk factors
- Moderate CKD (Stage 3: eGFR 30-59 mL/min/1.73 m²)
- DM without target damage
- DM ≥10 years or with another risk factor
- European HeartScore ≥5% and <10% 10 year risk of fatal CVD
Lipid Goals:
- LDL-C <70 mg/dL "and" ≥50% reduction from "baseline"
- Non-HDL-C <100 mg/dL
- ApoB <80 mg/dL
Moderate Risk
Risk Factors:
- Young patients (T1DM <35 years, T2DM <50 years) with DM <10 years, without other risk factors
- European HeartScore ≥1% and <5% 10 year risk of fatal CVD
Lipid Goals:
- LDL-C <100 mg/dL
Low Risk
Risk Factors:
- European HeartScore <1% 10 year risk of fatal CVD
Lipid Goals:
- LDL-C <116 mg/dL
All Patients
Consider:
- Lipoprotein a (Lp(a)): Considered at least once in every adult's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (430 nmol/L). Considered in those with family history of premature CVD. Considered for reclassification of risk in borderline cases.
- Triglycerides: TG <150 mg/dL indicates lower risk; TG >150 mg/dL, look for other risk factors
- Diabetes: A1C <7%
2014 National Lipid Association Management of Dyslipidemia Guidelines
Very High Risk
Risk Factors:
- ASCVD
- DM - Type 1 or 2 with ≥2 other major ASCVD risk factors or end organ damage (microalbuminuria ≥30 mg/g, CKD, retinopathy)
Lipid Goals:
- LDL-C <70 mg/dL and >50% reduction from baseline
- Non-HDL <100 mg/dL
- ApoB <80 mg/dL
High Risk
Risk Factors:
- LDL-C ≥190 mg/dL - severe hypercholesterolemia, including FH
- CKD ≥Stage 3B
- DM with 0-1 other major ASCVD risk factors
Lipid Goals (High, Moderate, Low Risk - Primary Prevention):
- LDL-C <100 mg/dL
- Non-HDL <130 mg/dL
- ApoB <90 mg/dL
2018 AHA/ACC Guidelines
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
The AHA/ACC Cholesterol guidelines are best summed up with their recommendations regarding secondary prevention (ASCVD) and primary prevention. These guidelines represent a more conservative approach compared to the ESC/EAS recommendations.
Expert Opinion: Advanced Atherosclerosis
Beyond published guidelines, expert consensus statements offer additional insight:
Advanced atherosclerosis:
- LDL-C range between 20-40 mg/dL
- Based upon PCSK9i trials: FOURIER, ODYSSEY, GLAGOV
- Expert Opinion White Paper: "There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision"
- A patient centered discussion may be had to discuss safety, efficacy and cost ratios
Other Notable Guidelines
So Which Guidelines Do I Follow?
In our opinion, that is up to the joint decision making of the patient and their care team.
There are numerous Cholesterol guidelines published by various organizations and medical societies around the globe. Some are more conservative than others. Some are more popular than others and get more attention. That doesn't always mean they are the most applicable to each unique patient with their own unique characteristics and circumstances.
Our mission at CardioAdvocate.com is to eradicate atherosclerotic cardiovascular disease in everyone. We wish to make published resources and expert recommendations more available, thereby facilitating a more informed personalized discussion.
In our highest risk patients, such as The Repeat Offender (The Heart Attack Survivor) we tend to align ourselves with the more aggressive lipid lowering recommendations, to include expert consensus opinion, rather than the more conservative recommendations of others, despite their popularity.
"LDL-C levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients" - 2019 Joint ESC/EAS Dyslipidemia Guidelines
Put another way by Dr. John Kastelein at the ESC meeting in 2019: "LDL-C is a toxic agent that in principle needs eradication, but in practice needs early, long-term and aggressive lowering"
Conservative vs. Aggressive Approaches
By way of comparison, the more conservative 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol calls for a more conservative LDL-C threshold of 70 mg/dL for the addition of non-statins to maximally tolerated statins. It also calls for multiple major ASCVD events to occur or to have had a major ACVD event combined with multiple risk factors before the most aggressive action is taken.
2025 ESC/EAS Focused Update — Breaking the Sisyphean Cycle?
In January 2026, Kausik Ray and Florian Kronenberg published a commentary in Atherosclerosis titled "Seventeen Years to Change Practice." The title alone says everything. Despite decades of evidence, it takes on average 17 years for medical guidelines to reach routine clinical care. The 2025 ESC/EAS Focused Update on dyslipidaemia management aims to break this cycle.
Key Shifts in the 2025 ESC/EAS Focused Update:
- Risk Assessment Modernized: SCORE2 and SCORE2-OP now factor in both fatal and non-fatal events and extend risk prediction up to age 89. Critically, this corrects years of underestimating risk in women and younger individuals.
- Expanded Lipid-Lowering Toolbox: New therapies include bempedoic acid, evinacumab, inclisiran, and high-dose icosapent ethyl — specifically not EPA+DHA mixtures.
- ACS Management Shift: The outdated "stepwise" escalation approach is replaced by immediate high-intensity statin plus ezetimibe for most patients post-ACS.
- Lp(a) Testing Standardized: Universal Lp(a) testing recommended at least once in adulthood, optimally with the first lipid profile. Lp(a) is positioned as a continuous, risk-enhancing factor.
- New Extreme Risk Category: Patients with recurrent ASCVD events despite intensive therapy now have dedicated recognition and treatment guidance.
The Implementation Gap: JACC Stats 2026
Following the release of the 2025 ESC/EAS Focused Update, the inaugural JACC Cardiovascular Statistics 2026 (Wadhera et al.) report delivered a sobering reality check. Despite therapeutic advances — PCSK9 inhibitors, inclisiran, bempedoic acid, ezetimibe — population-level cardiovascular health has stalled or reversed:
- LDL-C targets: Most high-risk patients still fail to reach guideline-recommended LDL-C goals
- Statins underused: Even among patients with established ASCVD, statin prescribing and adherence remain suboptimal
- Young adult MI rising: After years of decline (2004–2010), MI hospitalizations in young adults are increasing again — driven by obesity, diabetes, and metabolic syndrome
- Obesity epidemic: Now affects >40% of U.S. adults, up from 34.5% in 2011–2012
2026 ACC/AHA/NLA Dyslipidemia Guidelines: The Landscape Shifts
On March 13, 2026, the ACC/AHA published the landmark 2026 Guideline on the Management of Dyslipidemia (Blumenthal RS, et al., JACC 2026 — JACC link, also published in Circulation). This 102-page document retires and replaces the 2018 Blood Cholesterol guidelines and represents the most comprehensive U.S. lipid guideline ever published. Even the name change tells the story — this is no longer just about cholesterol. It's about dyslipidemia in all its forms.
PREVENT-ASCVD: A New Risk Calculator
The Pooled Cohort Equations (PCE) have been replaced by the PREVENT-ASCVD equations (COR 1, LOE B-NR). PREVENT was derived from approximately 3.3 million contemporary U.S. adults (versus ~25,000 for PCE). PREVENT estimates are 40-50% lower than PCE for the same risk profile. New thresholds: Low <3%, Borderline 3-<5%, Intermediate 5-<10%, High ≥10%. Race/ethnicity is NOT a variable (it is a social construct, not a biologic predictor). PREVENT also provides 30-year risk estimation and heart failure prediction. Optional inputs include HbA1c, albumin/creatinine ratio, and zip code for social deprivation index.
CPR Framework: Calculate-Personalize-Reclassify
The 2026 guidelines introduce a formal 3-step framework (Figure 5 in the guideline):
- Calculate: Use PREVENT-ASCVD for 10-year and 30-year risk
- Personalize: Discuss risk with patient, evaluate risk enhancers (family history, ethnicity, Lp(a), hsCRP, metabolic syndrome, albuminuria, etc.)
- Reclassify: If uncertainty remains after shared decision-making, use coronary artery calcium (CAC) scoring to reclassify risk
This is a memorable, structured approach that gives clinicians a clear pathway. CPR — it saves lives in more ways than one.
Absolute Treatment Goals Are Back
After 13 years of "percentage reduction only" in U.S. guidelines, concrete LDL-C and non-HDL-C number goals have returned. This is a massive shift. The 2026 guidelines now align U.S. recommendations closely with the ESC approach for the first time:
| Risk Category | LDL-C Goal | Non-HDL-C Goal | Optional ApoB Goal |
|---|---|---|---|
| Secondary Prevention (Very High Risk) | <55 mg/dL | <85 mg/dL | <55 mg/dL |
| Secondary Prevention (Not Very High Risk) | <70 mg/dL | <100 mg/dL | <70 mg/dL |
| Primary Prevention High Risk (≥10%) | <70 mg/dL | <100 mg/dL | — |
| Primary Prevention Borderline/Intermediate | <100 mg/dL | <130 mg/dL | — |
Note: CardioAdvocate has long advocated for absolute goals. The return of specific LDL-C and non-HDL-C targets validates this position, and the transatlantic consensus is now here.
Universal Lp(a) Screening: COR 1
For the first time, a major U.S. guideline recommends measuring Lp(a) at least once in all adults (COR 1, LOE B-NR). Elevated Lp(a) is defined as ≥125 nmol/L (or ≥50 mg/dL). Very high Lp(a) is ≥200 nmol/L (≥75 mg/dL). In patients with ASCVD and elevated Lp(a) not at goal, PCSK9 mAbs are specifically recommended (COR 1, LOE B-R). This is a sea change from 2018 when Lp(a) was merely a "risk enhancer" with no formal testing recommendation.
ApoB Gets a Seat at the Table
ApoB measurement is now COR 2a for adults on lipid-lowering therapy with ASCVD, metabolic dysfunction, diabetes, or elevated triglycerides. Optional ApoB goals: <55, <70, or <90 mg/dL depending on risk category. Non-HDL-C and ApoB are formally recognized as better than LDL-C alone for assessing atherogenic risk in hypertriglyceridemia.
New Drugs in the Arsenal
Five new FDA-approved therapies since 2018:
- Bempedoic acid (COR 2a) — Oral ACL inhibitor, now approved in both primary AND secondary prevention. The CLEAR Outcomes trial demonstrated benefit. Available as combination pill with ezetimibe (Nexlizet).
- Inclisiran (COR 2a) — siRNA targeting PCSK9, dosed every 6 months. Positioned as second-line PCSK9 inhibition (after mAbs) because CVOT results (ORION 4, VICTORION-2 PREVENT) still pending.
- Evinacumab (COR 2b) — ANGPTL3 inhibitor for homozygous familial hypercholesterolemia, works independently of LDL receptors.
- Olezarsen (COR 1, LOE B-R) — ApoC-III inhibitor for familial chylomicronemia syndrome.
- Evolocumab in primary prevention — VESALIUS-CV trial demonstrated 25% reduction in first cardiovascular events.
Important: The 2026 guidelines no longer require ezetimibe before PCSK9 mAb. Drug selection is now based on degree of LDL-C lowering needed and patient preference/convenience. If a patient needs a 60% LDL-C reduction, you can go straight to a PCSK9 mAb. This is a game-changer for getting high-risk patients to goal faster.
VESALIUS-CV: PCSK9 Inhibitors Proven in Primary Prevention
A landmark development: VESALIUS-CV (Amgen, presented AHA 2025) enrolled 12,257 high-risk patients WITHOUT prior MI or stroke on maximally tolerated statins. Evolocumab reduced MACE by 25% (HR 0.75, 95% CI 0.65-0.86) over 4.6 years, achieving median LDL-C ~45 mg/dL. This is the first PCSK9 inhibitor trial to show benefit in primary prevention, bridging the gap between FOURIER (secondary prevention) and the new guideline recommendation to treat high-risk primary prevention patients aggressively. (ACC Coverage of VESALIUS-CV)
Supplements Formally Rejected: COR 3 No Benefit
For the first time, a major U.S. lipid guideline says do not use dietary supplements for LDL-C or triglyceride lowering. The SPORT trial showed rosuvastatin 5 mg beat ALL six tested supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice). CoQ10 also received COR 3: No Benefit for treating or preventing statin-attributed muscle symptoms.
CAC Scoring: From Tiebreaker to Centerpiece
The 2026 guidelines provide the most detailed CAC guidance ever in a U.S. guideline. Specific CAU-based tiered recommendations:
- CAC = 0: Reasonable to defer lipid-lowering therapy (exceptions: FH, diabetes, smoking, strong family history)
- CAC 1-99, <75th percentile: Moderate-intensity statin, goal LDL-C <100
- CAC ≥100 or ≥75th percentile: Start lipid-lowering therapy, goal LDL-C <70
- CAC 300-999: Goal LDL-C <70, non-HDL-C <100
- CAC ≥1000: Treat like secondary prevention — goal LDL-C <55, non-HDL-C <85
- Incidental CAC on noncardiac CT: COR 1 — should be considered in treatment decisions
Special Populations — New Firsts
Brief summary of guideline updates for special populations:
- HIV: First-ever COR 1 for statin therapy based on REPRIEVE trial (pitavastatin 4 mg showed 35% MACE reduction)
- CKD Stage 3+: Dedicated recommendations — moderate-intensity statin + ezetimibe (COR 1)
- Pregnancy: Nuanced approach — very high risk FH/ASCVD patients may continue statins (COR 2b); previously a blanket "stop all statins"
- HFrEF without ASCVD: Upgraded to COR 3: No Benefit (from COR 2b in 2018) — CORONA, GISSI-HF trials demonstrated no benefit
Questions to Ask Your Care Team
- Is my clinician using the 2026 PREVENT calculator or the older Pooled Cohort Equations? The risk categories have changed with the new 2026 guidelines.
- What is my LDL-C goal number? The 2026 guidelines restored specific targets — I should know mine.
- Should I get a coronary artery calcium scan? The 2026 guidelines now have specific treatment recommendations based on CAC score thresholds.
- Has my Lp(a) been checked? The 2026 guidelines recommend universal screening at least once in every adult's lifetime.
- What is my ApoB level? The 2026 guidelines now formally recommend ApoB measurement for certain high-risk patients on lipid-lowering therapy.
- I had a heart attack — should I be on combination therapy now rather than waiting to see if statins alone work?
- Are you considering my risk based on multiple guidelines, including the 2026 ACC/AHA approach?
- Are there lipid medications I should avoid due to potential side effects?
- Should I be monitoring my liver enzymes or muscle symptoms while on lipid-lowering therapy?
- How often should my lipid levels be checked and what follow-up plan do we have?
The Bottom Line
Guidelines keep improving. But as Ray and Kronenberg point out, without a fundamental change in how we implement evidence, we risk repeating the Sisyphean cycle — rolling the boulder up the hill only to watch it roll back down. CardioAdvocate exists to help close that gap.
The 2013 ACC/AHA guidelines represented a well-intentioned but ultimately flawed interpretation of what "evidence-based medicine" should be. By restricting themselves to RCT data alone, guideline writers inadvertently created a situation where patients were potentially undertreated.
Fortunately, the broader medical community — including ESC/EAS, AACE/ACE, NLA, and other stakeholders — continued to provide more aggressive recommendations grounded in clinical expertise and a broader interpretation of the evidence base.
The path forward requires:
- Patient-centered care informed by multiple guidelines
- Recognition that guidelines are starting points, not endpoints
- Access to specialist input when patients fall outside standard categories
- Regular monitoring and reassessment of lipid levels
- Aggressive treatment of highest-risk patients, not complacency
Don't accept undertreatment simply because you're "following the guidelines." Ask your care team which guidelines they're using, why they chose those guidelines, and whether your individual circumstances warrant a more aggressive approach. The guidelines are there to guide you — not to limit you.
February 2026 Update: The inaugural JACC Cardiovascular Statistics 2026 (Wadhera et al., PubMed) report confirms the implementation gap remains the real crisis — most high-risk patients still fail to reach LDL-C targets, statins remain underused, and young adult MI hospitalizations are rising. Meanwhile, innovation continues: twice-yearly injectable lipid-lowering therapies (including long-acting PCSK9 inhibitors and siRNA agents like inclisiran) could dramatically reduce lifetime cholesterol burden and solve the adherence problem that undermines even the best guidelines. The question is no longer whether we have the tools — it's whether we use them.
March 2026 Update: The 2026 ACC/AHA/NLA Dyslipidemia Guidelines represent the most significant shift in U.S. lipid management in over a decade. PREVENT replaces the Pooled Cohort Equations. Absolute LDL-C and non-HDL-C goals are back. Universal Lp(a) screening is now Class I. Five new drugs have entered the algorithm. Supplements are formally rejected. And CAC scoring has evolved from a tiebreaker to a clinical decision-making centerpiece. After years of the U.S. lagging behind European guidelines, the gap has narrowed dramatically. CardioAdvocate's position — treat aggressively, measure comprehensively, and never accept therapeutic inertia — has never been more aligned with mainstream guidance.
Foot Stompers: Key Takeaways
Reference
Ray KK, Kronenberg F. "Seventeen Years to Change Practice: Will the 2025 ESC/EAS Dyslipidaemia Guidelines Finally Break the Sisyphean Cycle?" Atherosclerosis 2026;120636.
Recommended Resources
Guidelines and Position Statements
- 2026 ACC/AHA/NLA Guideline on the Management of Dyslipidemia (JACC)
- 2026 ACC/AHA/NLA Guideline on the Management of Dyslipidemia (Circulation)
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias
- 2025 ESC/EAS Focused Update on dyslipidaemia management
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- AACE/ACE Consensus Statement on the Management of Dyslipidemia — 2020
- 2014 National Lipid Association Management of Dyslipidemia Guidelines
- 2004 ATP III Report on High Blood Cholesterol (Historical Reference)
Risk Assessment Tools
- PREVENT-ASCVD Calculator (AHA) — 10-year and 30-year risk estimation (2026)
- Mayo Clinic Statin Choice Decision Aid — Multiple risk calculators including ACC/AHA PCE, Reynolds, Framingham
- European HeartScore — Risk prediction tool for European populations
- SCORE2 and SCORE2-OP — Updated risk assessment (2025 ESC/EAS)
Specialist Resources
- LearnYourLipids — Find a cardiometabolic specialist or lipidologist
- Expert Thought Leaders: John Kastelein (@JohnKastelein) on X
- Expert Thought Leaders: Thomas Dayspring (@Drlipid) on X
Related CardioAdvocate Content
- The Repeat Offender (The Heart Attack Survivor) — Secondary prevention and aggressive lipid lowering
- Hiding in Plain Sight: Familial Hypercholesterolemia
- A Picture is Worth a Thousand Words: Coronary Artery Calcium Scores
- Little Napoleon Complex: Lipoprotein (a)
- Atherogenic Triad — The dangerous lipid phenotype associated with visceral adiposity
